newwin
Luciann Nguyen
Settings
← Accounts
academic

HUYABIO International, LLC.

52
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

HUYABIO International, LLC.

New trial — A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

New trialNCT05163028
52/100
Opportunity
Commercial fit11/25
Clinical timing19/20
Biomarker need5/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 1 trial NCT05163028 posted by HUYABIO International, LLC.: "A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations". New trial on a phase 1 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 349 days ago.

ConfidenceHigh · 87%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT05163028
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
phase 1
mol. elig.